NCT06361043Recrutement en cours
Conebeam CT-based Online Adaptive Radio-Therapy for Esophageal Cancer (ARTEC)
Résumé
Despite multimodal therapy, patients with esophageal cancer have poor prognosis with 5-year overall survival around 25%. Considering tumor-related death as main reason for high mortality rate in those patients, treatment-related cardio-pulmonary toxicities could also play a role in this regard. Online adaptive radiotherapy offers the possibility for daily re-planning and therefore helps radiation oncologists to better spare the organs at risk and reduce radiation-induced toxicity. Tha aim of ARTEC is to assess the pulmonary toxicity in patients with esophageal cancer treated with online adaptive radiotherapy.
Critères d'inclusion
• Written informed consent • Histologically confirmed diagnosis of AC (Adenocarcinoma) or SCC (squamos cell carcinoma) of the thoracic esophagus or gastroesophageal junction (Siewert I-II) • Patients with cT2-4b cN0 cM0 or cTany cN+ cM0 or any patient with early stage EC ineligible for upfront surgery • Age \>= 18 years old • Karnofsky Performance Status (KPS) \>= 70 or ECOG (Eastern Cooperative Oncology Group) 0 - 1 • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with patients before registration in the trial
Critères d'exclusion
• Cervical esophageal cancers (15-18 cm from the incisors) • Definitive clinical or radiologic evidence of metastatic disease • Any active malignancy within 2 years of study registration that may alter the course of esophageal cancer treatment • Prior thoracic radiotherapy that would result in overlap of radiation therapy fields • Induction chemotherapy for the current malignancy prior to RCHT is allowed if last dose is no more than 90 days and no less than 10 days prior to registration • Pregnant and/or breast-feeding females
Contacts
Les coordonnées de l'équipe de l'essai s'affichent sur demande.
Voir la fiche officielle de l'essai- Statut
- Recrutement en cours
- Phase
- —
- Type d'étude
- Observationnelle
- Pays
- Suisse
- Promoteur
- Insel Gruppe AG, University Hospital Bern(Autre)
- N° de protocole
- 2023-01833
- Pathologies
- Esophageal Cancer
- Interventions
- —
Lieux · 1
- Bern, SuisseInselspital, University of Berne, Deparftment of Radio-OncologyRecrute dans ce centre
Au total, dans le monde, le seul centre listé au registre recrute.
Statut par centre selon le registre ClinicalTrials.gov (dernière mise à jour publiée : 25 avril 2024).
Ce statut peut avoir changé et ne dit rien de votre éligibilité : avant toute démarche, vérifiez avec votre oncologue ou le centre.
Autres identifiants
- 2023 · financement NIH
Voir aussi
Autres versions
Ces résultats sont indicatifs et ne remplacent pas un avis médical — à discuter avec votre médecin.